tirzepatide cardiovascular outcomes study SUMMIT: Improves and Quality of Life For Patients With HFpEF and Obesity tirzepatide cardiovascular outcomes A comparison

Peptide therapies may be discussed or prescribed when clinically appropriate after evaluation by a licensed healthcare provider

Suryavanshi, M

5.3%) in head-to-head trials for type 2 diabetes results that should translate powerfully to obesity

Warnings A varied, balanced diet and a healthy lifestyle are important for health.Not suitable for pregnant women, nursing and children.Do not use as a replacement for a balanced and varied diet.Keep out of reach of small children

In December 2025, Eli Lilly announced topline results from the phase-3 TRIUMPH-4 clinical trial evaluating the safety and efficacy of retatrutide in adults with obesity or overweight and knee osteoarthritis, and without diabetes, as an adjunct to healthy diet and physical activity.

Always talk to your doctor about these risks